Cytokines News and Research

Latest Cytokines News and Research

Tumor necrosis factor can suppress inflammation, treat rheumatoid arthritis

A new study by rheumatologists at Hospital for Special Surgery in New York has shown that a powerful pro-inflammatory protein, tumor necrosis factor, can also suppress aspects of inflammation.

23 May 2011

Pfizer's axitinib Phase 3 trial in advanced renal cell carcinoma meets primary endpoints

Pfizer Inc. today announced data from the pivotal Phase 3 AXIS 1032 trial, showing that in patients with previously treated advanced renal cell carcinoma, axitinib significantly extended progression-free survival at the 47th Annual American Society of Clinical Oncology meeting in Chicago from June 3-7, 2011.

19 May 2011

Anacor Pharmaceuticals initiates AN2728, AN2898 Phase 2 trial in mild-to-moderate atopic dermatitis

Anacor Pharmaceuticals announced today that the first patient has been dosed in a Phase 2 trial of AN2728 and AN2898 to determine safety, tolerability and efficacy of the two compounds for the topical treatment of mild-to-moderate atopic dermatitis.

18 May 2011

UCLA researchers amp up power of killer CD8 T-cells to fight melanoma

Researchers with UCLA's Jonsson Comprehensive Cancer Center have discovered a way to amp up the power of killer T-cells, called CD8 cells, making them more functional for longer periods of time and boosting their ability to multiply and expand within the body to fight melanoma, a new study has found.

11 May 2011

Techne acquires Tocris Holdings

Techne Corporation announced today that it has acquired 100% ownership of Tocris Holdings Limited and subsidiaries, a leading supplier of reagents for non-clinical life science research.

3 May 2011

Top-line results from Pfizer's tofacitinib Phase 3 studies in RA

Pfizer Inc. announced today top-line results from the ORAL Standard and ORAL Step Phase 3 studies of tofacitinib, an investigational, novel, oral JAK inhibitor.

29 Apr 2011

Study shows neutralizing antibodies against GM-CSF can halt MS development

The neutralization of the cytokine GM-CSF could halt the development of multiple sclerosis. This was demonstrated by the research team of the immunologist Burkhard Becher at the University of Zurich in an animal model.

25 Apr 2011

Anacor's AN2728 and GSK '052 new data to be presented at upcoming meetings

Anacor Pharmaceuticals announced today that it will present data on two of its compounds at the following conferences: “Safety and efficacy of AN2728 ointment in a phase 2b dose-ranging bilateral study of mild-to-moderate plaque psoriasis”.

25 Apr 2011

Idera announces delay in commencement of IMO-2125 Phase 2 clinical trial in treatment-naive HCV patients

Idera Pharmaceuticals, Inc. today announced that it has chosen to delay initiating its planned Phase 2 clinical trial of IMO-2125 based on preliminary data from a 26-week nonclinical toxicology study of IMO-2125 in rodents. The Phase 2 clinical trial involves the evaluation of IMO-2125 plus ribavirin in treatment-naïve, genotype 1 hepatitis C virus (HCV) patients.

22 Apr 2011

TRIM5 cellular protein helps rhesus monkeys resist HIV

Thanks to a certain protein, rhesus monkeys are resistant to HIV. Known as TRIM5, the protein prevents the HI virus from multiplying once it has entered the cell. Researchers from the universities of Geneva and Zurich have now discovered the protein's mechanism, as they report in Nature. This also opens up new prospects for fighting HIV in humans.

21 Apr 2011

Ludwig Institute demonstrates ability of DAVANAT to enhance efficacy of T-lymphocytes to kill tumor cells

Pro-Pharmaceuticals, Inc. today announced that the Brussels Branch of the Ludwig Institute for Cancer Research demonstrated the ability of GM-CT-01 (DAVANAT®) to enhance the ability of tumor-specific T-lymphocytes to kill tumor cells.

20 Apr 2011

AMIA honors UTMB professor with Distinguished Paper Award for translational bioinformatics

Suresh Bhavnani, an associate professor of biomedical informatics in the Institute for Translational Sciences at the University of Texas Medical Branch at Galveston, was recently honored for using advanced visual analytical methods to propose a new classification of asthma patients.

19 Apr 2011

Chronic exposure to polluted air can lead to inflammation

Chronic inhalation of polluted air appears to activate a protein that triggers the release of white blood cells, setting off events that lead to widespread inflammation, according to new research in an animal model.

16 Apr 2011

Top-line results from Pfizer's tofacitinib Phase 3 study in rheumatoid arthritis

Pfizer Inc. announced today top-line results from the ORAL Scan Phase 3 study of tofacitinib, formerly known as tasocitinib, an investigational, novel, oral JAK inhibitor.

15 Apr 2011

New treatment improves immune function in 13-year-old with Wiskott-Aldrich syndrome

In a novel approach that works around the gene defect in Wiskott-Aldrich syndrome, an inherited immune deficiency disorder, researchers used an alternative cell signaling pathway to significantly improve immune function in a 13-year-old boy with the disease.

15 Apr 2011

Study shows neutralizing antibodies to C5a protein may prevent heart failure

New research published online in The FASEB Journal details research in rats and mice that offers hope for stopping the devastating, and often fatal, effects of sepsis in humans. In the study, University of Michigan researchers show how neutralizing the effects of a key protein fragment, called C5a, used by the immune system to attract white blood cells may ultimately prevent heart failure.

12 Apr 2011

Scientists identify novel mechanism to control cancer spread

Saint Louis University researchers have identified a novel mechanism to control the traffic of cells and fluid from tissues to lymphatic vessels. It may be possible to harness this mechanism to fight cancer spread from one organ to another organ and improve the effectiveness of vaccines.

11 Apr 2011

A2AAR-selective agonists may prevent permanent vision damage from traumatic optic nerve injury

Scientists want to protect the optic nerve when the eye takes a blow on the battlefield or in a car wreck.

7 Apr 2011

TZDs might serve as new agents for addiction treatment

Thiazolidinediones are a class of medications that are commonly prescribed to treat type-2 diabetes, while fibrates are a structurally-related class of medications that are prescribed to modulate lipid levels in both diabetic and non-diabetic patients to help reduce the risk of cardiovascular disease.

6 Apr 2011

Idera presents IMO-3100 Phase 1 trial data in autoimmune diseases at Keystone Symposia

Idera Pharmaceuticals, Inc. today announced the presentation of data from its multiple-dose Phase 1 clinical trial of IMO-3100 in healthy subjects.

5 Apr 2011

Cytokines News and Research

Latest Cytokines News and Research

Tumor necrosis factor can suppress inflammation, treat rheumatoid arthritis

Pfizer's axitinib Phase 3 trial in advanced renal cell carcinoma meets primary endpoints

Anacor Pharmaceuticals initiates AN2728, AN2898 Phase 2 trial in mild-to-moderate atopic dermatitis

UCLA researchers amp up power of killer CD8 T-cells to fight melanoma

Techne acquires Tocris Holdings

Top-line results from Pfizer's tofacitinib Phase 3 studies in RA

Study shows neutralizing antibodies against GM-CSF can halt MS development

Anacor's AN2728 and GSK '052 new data to be presented at upcoming meetings

Idera announces delay in commencement of IMO-2125 Phase 2 clinical trial in treatment-naive HCV patients

TRIM5 cellular protein helps rhesus monkeys resist HIV

Ludwig Institute demonstrates ability of DAVANAT to enhance efficacy of T-lymphocytes to kill tumor cells

AMIA honors UTMB professor with Distinguished Paper Award for translational bioinformatics

Chronic exposure to polluted air can lead to inflammation

Top-line results from Pfizer's tofacitinib Phase 3 study in rheumatoid arthritis

New treatment improves immune function in 13-year-old with Wiskott-Aldrich syndrome

Study shows neutralizing antibodies to C5a protein may prevent heart failure

Scientists identify novel mechanism to control cancer spread

A2AAR-selective agonists may prevent permanent vision damage from traumatic optic nerve injury

TZDs might serve as new agents for addiction treatment

Idera presents IMO-3100 Phase 1 trial data in autoimmune diseases at Keystone Symposia

CellVoyant's AI-Powered Vision for the Future of Cell Therapy

Scalable, Smart, and Accessible: The Future of Lab Automation

Healthy Beginnings, Hopeful Futures: A Conversation with WHO’s Dr. Allotey

Cytokines News and Research

Latest Cytokines News and Research

CellVoyant's AI-Powered Vision for the Future of Cell Therapy

Scalable, Smart, and Accessible: The Future of Lab Automation

Healthy Beginnings, Hopeful Futures: A Conversation with WHO’s Dr. Allotey

Newsletters you may be interested in